Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Big Pharma Retreats from UK as AstraZeneca Pauses $271M Expansion

AstraZeneca has halted its planned £200 million ($271 million) expansion in Cambridge, England, joining a growing list of pharmaceutical giants reconsidering their investments in the United Kingdom. This decision marks the latest in a series of setbacks for the UK's life sciences sector, as major players in the industry express concerns over the country's commitment to supporting innovation in medicines and vaccines.

NoahAI News9/13/2025

Neurescue's Breakthrough Device for Non-Shockable Cardiac Arrests Gains European Approval

Neurescue, a medical device company and former Fierce Medtech Fierce 15 winner, has received European approval for its innovative smart balloon catheter, marking a significant advancement in the field of resuscitation for non-shockable cardiac arrests. This groundbreaking device aims to address a critical gap in treatment options for the majority of cardiac arrest patients, potentially impacting millions of lives annually.

NoahAI News9/13/2025

AbbVie Secures Extended Exclusivity for Rinvoq, Bolstering Post-Humira Strategy

AbbVie has successfully negotiated a settlement with generic drugmakers, extending the market exclusivity of its JAK inhibitor Rinvoq in the United States until 2037. This strategic move adds four years to Rinvoq's exclusivity period, reinforcing AbbVie's efforts to maintain a strong position in the immunology market as sales of its blockbuster drug Humira decline.

NoahAI News9/12/2025

Intercept Pharmaceuticals Withdraws Liver Drug Ocaliva from US Market Amid Regulatory Challenges

Intercept Pharmaceuticals has announced the withdrawal of its liver disease drug Ocaliva (obeticholic acid) from the US market, marking the end of a tumultuous journey for the once-promising treatment. The decision comes in response to a request from the US Food and Drug Administration (FDA), which has also placed a clinical hold on trials of obeticholic acid conducted under US investigational new drug applications.

NoahAI News9/12/2025

Pharmaceutical Industry Sees Executive Moves, Clinical Advances, and Legal Challenges

Takeda Pharmaceutical has announced a significant leadership change, appointing Rhonda Pacheco as the new head of its U.S. business unit, effective September 29. Pacheco, who has over a decade of experience at Eli Lilly, most recently served as group vice president of the cardiometabolic health unit, overseeing the successful launches of Lilly's GLP-1 drugs. She will succeed Julie Kim, who is set to take over as CEO in June 2026, replacing the retiring Christophe Weber.

NoahAI News9/12/2025

GLP-1 Drugs Show Promise Beyond Weight Loss: Potential Applications in Cancer Treatment

In a groundbreaking development, researchers are exploring the potential of GLP-1 drugs, known primarily for their weight loss benefits, in cancer treatment. This unexpected application of popular medications like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, could revolutionize oncology care.

NoahAI News9/12/2025

CVS Health Announces Leadership Changes in Care Delivery Businesses

CVS Health, a major player in the healthcare industry, has unveiled significant leadership changes in its care delivery businesses. These shifts come as the company continues to integrate its recent acquisitions and streamline operations across its diverse healthcare portfolio.

NoahAI News9/12/2025

AI Drives Investment and Acquisitions in Medical Technology Sector

Artificial intelligence (AI) is emerging as a significant driver of investment and acquisition activity in the medical technology sector in 2025, according to recent industry reports and transactions.Despite a overall decrease in funding rounds during the first half of 2025, AI-focused startups have become increasingly attractive to investors. A recent report by PitchBook highlights this trend, with AI companies in the medical technology space receiving preferential treatment from venture capitalists and other investors.

NoahAI News9/12/2025

Neuroscience Biotech LB Pharma Breaks IPO Drought with Upsized $285M Offering

LB Pharma has successfully launched its initial public offering (IPO) on the Nasdaq, raising $285 million in a landmark debut that ends a seven-month drought for biotech IPOs. The neuroscience-focused company, led by former Carmot Therapeutics CEO Heather Turner, sold 19 million shares at $15 each, surpassing its initial target of $228.5 million.

NoahAI News9/12/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Financial Pressures

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions as companies reevaluate their priorities and attempt to extend cash runways in a challenging economic environment. Major players and smaller biotechs alike are making difficult decisions to streamline operations and focus on core programs.

NoahAI News9/12/2025

Biopharma Job Market Faces Significant Challenges Amid Industry-Wide Layoffs

The pharmaceutical and biotechnology sectors are grappling with a tightening job market, as recent data reveals a substantial decrease in job openings and a wave of layoffs across the industry. This trend is creating a highly competitive environment for job seekers, with far-reaching implications for the workforce and companies alike.

NoahAI News9/12/2025

New York City's Life Sciences Sector Experiences Significant Growth and Challenges

New York City's life sciences sector has seen substantial growth over the past decade, positioning itself as an emerging hub in the industry. However, the city still faces challenges as it seeks to compete with more established centers like Boston and San Francisco. Recent data and insights from industry experts shed light on the progress made and the hurdles that lie ahead.

NoahAI News9/12/2025

«1 2 3 4...67 »